Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The safety and tolerability of single and multiple administration of DWP212525
The safety and tolerability of single and multiple administration of DWP212525 will be evaluated in healthy adult volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort1 | Experimental |
| |
| Cohort2 | Experimental |
| |
| Cohort3 | Experimental |
| |
| Cohort4 | Experimental |
| |
| Cohort5 | Experimental |
| |
| Cohort6 | Experimental |
| |
| Cohort7 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DWP212525 XXmg | Drug | DWP212525 XXmg |
|
| Measure | Description | Time Frame |
|---|---|---|
| PK profiles of DWP212525 | Area under the plasma drug concentration-time curve from 0 to last | Day 1 |
| PK profiles of DWP212525 | The maximum or peak concentration between zero and dosing interval | Day 1 |
| PK profiles of DWP212525 | Time of maximum concentration | Day 1 |
| Safety profiles | AE, SAE, etc. | Day 1 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Recruiting | Seoul | 03080 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001327 | Autoimmune Diseases |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cohort8 | Experimental |
|
| Cohort9 | Experimental |
|
| Cohort10 | Experimental |
|
| Cohort 11 | Experimental |
|
| DWP212525 placebo | Drug | DWP212525 placebo |
|